Synthesis of an insulin-loaded mucoadhesive nanoparticle designed for intranasal administration: focus on new diffusion media

Frontiers in Pharmacology

Pharmacology

Helgi B. Schiöth¹  Isaac Karimi²  Tahereh Jamshidnejad-Tosaramandani³  Soheila Kashanian⁴ 

[1]Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden

[2]Laboratory for Computational Physiology, Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran

[3]Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran

[4]Laboratory for Computational Physiology, Department of Biology, Faculty of Science, Razi University, Kermanshah, Iran

[5]Department of Surgical Sciences, Division of Functional Pharmacology and Neuroscience, Uppsala University, Uppsala, Sweden

[6]Nanobiotechnology Department, Faculty of Innovative Science and Technology, Razi University, Kermanshah, Iran

[7]Sensor and Biosensor Research Center (SBRC), Faculty of Chemistry, Razi University, Kermanshah, Iran

关键词: intranasal drug delivery;    mucoadhesive nanoparticles;    chitosan nanoparticles;    insulin;    poly-electric complexation;   

DOI  :  10.3389/fphar.2023.1227423

 received in 2023-06-01, accepted in 2023-07-18,  发布年份 2023

来源: Frontiers

【 摘 要 】

Intranasal administration is a drug delivery approach to provide a non-invasive pharmacological response in the central nervous system with relatively small peripheral side effects. To improve the residence time of intranasal drug delivery systems in the nasal mucosa, mucoadhesive polymers (e.g., chitosan) can be used. Here, insulin-loaded chitosan nanoparticles were synthesized and their physiochemical properties were evaluated based on requirements of intranasal administration. The nanoparticles were spherical (a hydrodynamic diameter of 165.3 nm, polydispersity index of 0.24, and zeta potential of +21.6 mV) that granted mucoadhesion without any noticeable toxicity to the nasal tissue. We applied a new approach using the Krebs–Henseleit buffer solution along with simulated nasal fluid in a Franz’s diffusion cell to study this intranasal drug delivery system. We used the Krebs–Henseleit buffer because of its ability to supply glucose to the cells which serves as a novel ex vivo diffusion medium to maintain the viability of the tissue during the experiment. Based on diffusion rate and histopathological endpoints, the Krebs–Henseleit buffer solution can be a substituent solution to the commonly used simulated nasal fluid for such drug delivery systems.

【 授权许可】

Unknown   
Copyright © 2023 Jamshidnejad-Tosaramandani, Kashanian, Karimi and Schiöth.